| Abstrakt: |
A recent study conducted at the University of Illinois has reported preliminary results on the use of GBT021601, a next-generation HbS polymerization inhibitor, for the treatment of sickle cell anemia (SCA). The study found that GBT021601 was well-tolerated and showed potential for reducing treatment burden and improving clinical outcomes. The study also observed an increase in hemoglobin levels and a reduction in adherent cells, which are potential biomarkers for vaso-occlusive crises (VOCs) in SCA. These findings support further clinical development of GBT021601 as a potential treatment for individuals with SCA. [Extracted from the article] |
